ON THE NOTION OF SYNERGY OF MONOCLONAL ANTIBODIES AS DRUGS

ON THE NOTION OF SYNERGY OF MONOCLONAL ANTIBODIES AS DRUGS

Blog Article

History of developing synergy between monoclonal antibodies, anti-tumor activity of monoclonal antibodies against tyrosine-kinases receptors EGFR/ErbB-1 and HER2/ErbB-2 as well as growth factor VEGF in various combinations are considered in the article.There were proposed hypotheses about potential molecular mechanisms underlay synergy between monoclonal antibodies (for fleshlight automatique homo- and hetero combinations of antibodies appropriately specific for ribavirin coupon antigenic determinants on the same or different receptors).Future trends in researches necessary to deeper understanding causes of this phenomenon and perspectives for practical application of monoclonal antibodies acted synergistically as immunotherapeutic drugs for human tumors treatment are reviewed.